Peter Moldt, Ph.D.
Partner, Novo Ventures (US), Inc.
Peter joined Novo Ventures (US) Inc. in San Francisco, California in 2012. He is a member of the Board of Directors of Bolt Therapeutics (chairman), E-Scape Bio., Aligos, Swift Health Systems/Inbrace and Viewpoint.
From 2009-2012, Peter was employed with Novo A/S as a partner in Novo Ventures in Denmark. In 2004, Peter co-founded Curalogic A/S, served as CEO until 2009 and took the company public in 2006. From 2000-2004, he was Chief Operating Officer of 7TM Pharma A/S, which he also co-founded. Previously, he worked for 11 years with NeuroSearch A/S, where he was responsible for all aspects of pre-clinical and clinical drug development.
Peter holds a PhD in medicinal chemistry from the Royal Danish School of Pharmacy. He has also been a post doc with Yale University’s department of organic chemistry.